First Choice Healthcare Q3 Loss Widens to $19.1M on $17.4M Conversion Interest; Going Concern Stands
FCHS has more than doubled off its 52-week low of $0.002.
Summary
First Choice Healthcare's Q3 10-Q shows a $19.1 million nine-month loss driven by $17.4 million of non-cash conversion interest, $135,212 of cash, and a repeated going concern warning, while the ~$650 million Wellgevity 360 merger and $21.3 million Pointe Med deal remain pending.
Key Events · Earnings and Guidance · FCHS
-
Nine-Month Loss Widens to $19.1M
Net loss was $19,129,123 for the nine months ended September 30, 2026 versus $3,500,214 a year earlier, with operating loss roughly flat at $1,957,683 and revenue at zero.
-
Conversion Interest Drives the Loss
Interest expense jumped to $17,369,765 from $2,143,153 after $23,706,824 of debt converted into 23,706 Series C preferred shares and 23,401 Series E shares were issued; this is a non-cash accounting charge, not a cash outflow.
-
Going Concern Doubt Reaffirmed
Management states substantial doubt about the ability to continue as a going concern within one year, citing a working capital deficit, $2,604,296 of operating cash burn, and only $135,212 of cash on hand.
-
Series E Terms Set Future Dilution
Series E preferred pays a 15% PIK dividend, is locked from conversion for 12 months, then converts at a 20% discount to the lowest five-day closing price with a floor set at 20% of the closing price and reset every six months.
Analysis · FCHS · Industrial Applications And Services
The nine-month net loss ballooned to $19,129,123 from $3,500,214 a year earlier, and almost all of the damage is non-operating: $17,369,765 of interest expense booked when holders converted discounted notes into Series C and Series E preferred stock. Operating loss was roughly flat at $1,957,683, and revenue was zero. The company still carries a working capital deficit, ended the period with $135,212 of cash, and management repeats that substantial doubt exists about continuing as a going concern. The real swing factor is the pending merger with Westin Acquisition Corp. into Wellgevity 360 at an equity value of up to about $650 million, paired with the $21,306,000 Pointe Med acquisition; both remain unconsummated and are conditioned on each other, registration effectiveness, stockholder approvals and financing. The Series E preferred converts after 12 months at a 20% discount to the lowest five-day closing price with a floor reset every six months, so future dilution is tied directly to the share price.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FCHS was trading at $0.00 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $115.4K. The 52-week trading range was $0.00 to $0.51. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.